Rivaara Labs

About Rivaara Labs

Rivaara Labs, established in 2019 by Bharat Daftary, operates as a vertically integrated molecular diagnostics company in India. Mr. Daftary, the erstwhile promoter of Bharat Serums & Vaccines Limited, founded Rivaara with the vision to address the gap in the widespread adoption of molecular diagnostics by making them more accessible and affordable. The management team includes Siddharth Daftary, who has a master's in Molecular & Genetic Medicine and an MBA, and spearheads the company's operations. Since its inception, the Mumbai-based company has secured significant funding, including a Series A round, to fuel its expansion.

The company's business model centers on establishing a widespread network of specialized Molecular Diagnostics (MDx) labs across India, with an ambition to grow from 12 to 60 labs to reduce sample processing times. Rivaara serves clinicians and patients by providing rapid and accurate diagnostic services. Revenue is generated from a portfolio of diagnostic tests and through partnerships with hospitals to set up in-house RT-PCR labs. The company develops and markets its own PCR-based test kits, created in collaboration with European research labs, which are specifically designed to detect pathogens prevalent in India.

Rivaara offers a comprehensive range of sample-to-answer molecular diagnostic services, focusing on infectious diseases, oncology, genetic disorders, and antibiotic resistance. The service portfolio includes automated RT-PCR tests, superior data analysis, and a LIMS interface that delivers actionable clinical reports. Key products include specialized panels like RespiQuik, SeptiQuik, and tests for tuberculosis and post-transplant infections, which enable early detection and targeted treatments. These PCR-based tests are designed to provide quick and affordable results, aiding in antimicrobial stewardship by reducing the unnecessary use of antibiotics.